Figure S3 from PCBP2 Mediates Olaparib Resistance in Breast Cancer by Inhibiting m⁶A Methylation to Stabilize PARP1 mRNA

Q: What type of study is this?

This is a Experimental Study study.

Zhaochang Qi; Lifang He; Zemei Xu; Xi Luo; Likeng Ji; Chuqi Lin; Armando E. Giuliano; Xiaojiang Cui; Zihao Deng; Jundong Wu; Stanley L. Lin; Yu Cui

doi:10.1158/0008-5472.30363406

October 15, 2025Open Access

Figure S3 from PCBP2 Mediates Olaparib Resistance in Breast Cancer by Inhibiting m⁶A Methylation to Stabilize PARP1 mRNA

View Full Paper

Ask AI

Bookmark

Share

Key Points

PCBP2 depletion accelerates PARP1 mRNA degradation, enhancing cancer treatment resistance.
The study highlights the role of m6A methylation in the regulation of mRNA stability.
Research indicates PCBP2 impacts olaparib efficacy, posing implications for breast cancer therapy.
Understanding this mechanism could lead to improved strategies against olaparib resistance in patients.

Implication

Analysis reveals PCBP2 regulates PARP1 mRNA stability in breast cancer, suggesting targets for olaparib resistance.

Abstract

Supplementary Figure S3 supports the Results section titled "Depletion of PCBP2 facilitates m6A methyltransferase complex recruitment and accelerates PARP1 mRNA degradation".

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Qi et al. (2025) studied this question.

synapsesocial.com/papers/68f199c5de32064e504dccf7 https://doi.org/10.1158/0008-5472.30363406

View Full Paper

Ask AI

Bookmark

Share

Figure S3 from PCBP2 Mediates Olaparib Resistance in Breast Cancer by Inhibiting m⁶A Methylation to Stabilize PARP1 mRNA

Key Points

Implication

Abstract

Discussion

Cite This Study

Figure S3 from PCBP2 Mediates Olaparib Resistance in Breast Cancer by Inhibiting m⁶A Methylation to Stabilize PARP1 mRNA

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers